Pricing erosion in US biosimilars
Competitive pressure and ASP declines in medical benefit products could impact margins.
BIOCON / Q4-FY26 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Chinese competition in insulin
Recent Chinese approvals in insulin could disrupt pricing and market share.
CRDMO revenue growth slowdown
Syngene's FY26 revenue grew only 3% YoY due to a large client impact; recovery uncertain.
Execution risk on new product launches
Ramp-up of aspart and aflibercept depends on capacity qualification and market adoption.